Abbott FreeStyle Libre 3 & Libre 3 Plus Glucose Sensor Accuracy Issues Investigation

Chimicles Schwartz Kriner & Donaldson-Smith LLP is investigating potential claims on behalf of individuals in the United States who purchased or used FreeStyle Libre 3 or FreeStyle Libre 3 Plus continuous glucose monitoring (“CGM”) sensors manufactured and sold by Abbott. On November 24, 2025, Abbott issued customer communications regarding certain affected sensors and the steps users should take.

Public reporting and regulator communications indicate that certain sensors from a specific production line may provide incorrect low glucose readings, which can create safety concerns if users rely on inaccurate information to make diabetes management decisions. The FDA advised that affected sensors should be discontinued and replaced.

Our firm is examining whether consumers paid for devices marketed as accurate and reliable without being informed of issues that could affect sensor performance, including potential out-of-pocket costs and other losses associated with replacing impacted sensors and supplies.

If you purchased or used a FreeStyle Libre 3 or FreeStyle Libre 3 Plus sensor and believe you may have an affected device—or received a notice advising you to discontinue or replace a sensor—please fill out the form below to share your experience. Submitting information is confidential, free, and does not obligate you to take any further action.

Freestyle Libre 3 (#872)

(*) Indicates required field: When communicating with us through this site or otherwise in connection with a matter for which we do not already represent you, your communication may not be treated as privileged or confidential, and does not create an attorney-client relationship between you and our Firm.